Table 2.
Treatment, complications and clinical outcome of patients with COVID-19.
| Characteristics | Total (n = 142) | Non-cardiac injury (n = 139) | Cardiac injury (n = 42) | P value |
|---|---|---|---|---|
| Time from onset to admission | 10 (7.15) | 10 (7.15) | 10 (7.15) | 1.000 |
| Treatment | ||||
| Antiviral drugs | 172 (95) | 132 (95) | 40 (95.2) | 1.000 |
| Antibiotics | 174 (96.1) | 133 (95.7) | 41 (97.6) | 1.000 |
| Glucocorticoids | 73 (40.3) | 44 (31.7) | 29 (69) | < 0.001 |
| Immunoglobulin therapy | 44 (24.3) | 26 (18.7) | 18 (42.9) | 0.001 |
| Oxygen inhalation | 135 (74.6) | 102 (73.4) | 33 (78.6) | 0.500 |
| Noninvasive ventilation | 34 (18.8) | 14 (10.1) | 20 (47.6) | < 0.001 |
| Invasive ventilation | 2 (1.1) | 0 (0) | 2 (4.8) | 0.053 |
| Complications | ||||
| ARDS | 26 (14.4) | 12 (8.6) | 14 (33.3) | < 0.001 |
| Acute kidney injury | 8 (4.4) | 4 (2.9) | 4 (9.5) | 0.086 |
| Hypoproteinemia | 55 (30.4) | 33 (23.7) | 22 (52.4) | < 0.001 |
| Anemia | 16 (8.8) | 12 (8.6) | 4 (9.5) | 0.767 |
| Hypoxemia | 55 (30.4) | 37 (26.6) | 18 (42.9) | 0.046 |
| Arrhythmias | 11 (6.1) | 5 (3.6) | 6 (14.3) | 0.02 |
| Clinical outcome | ||||
| Critical condition | 83 (45.9) | 47 (33.8) | 36 (85.7) | < 0.001 |
| Death | 34 (18.8) | 12(8.6) | 22 (52.4) | < 0.001 |